<cite index="3-2">Strides Pharma Science Ltd announced divestment of majority stake in its wholly-owned arm Pivot Path for Rs 100 crore to a consortium of investors led by Ascent Capital, along with co-investor Vintage</cite>

PE / VC 27 Jun 2026· ₹150 cr (stake + primary) · Completed· ✓ Verified

Strides will receive ₹75 crore at initial closing and ₹25 crore on the first anniversary of closing. Pivot Path provides consulting, regulatory compliance, digital transformation and technology-enabled services to pharmaceutical and life sciences companies; for FY26 it reported revenue of ₹144.7 crore and EBITDA of ₹16.9 crore, including revenue generated from services provided to Strides. Pivot Path received a ₹50 crore primary capital infusion to fund expansion and investments in technology, including AI-led platforms. The valuation was based on an independent assessment carried out by a Securities and Exchange Board of India (Sebi)-registered merchant banker.

Why it mattersPost-transaction shareholding: Strides 19.95%, investor consortium 65.05%, ESOP pool 15%, with Pivot Path reclassified as an associate company instead of a wholly-owned subsidiary-a key structuring mechanism allowing the parent to monetize without full exit while retaining upside participation and maintaining operational visibility as an associate.
CounselALMT Legal, Bangalore
SectorPharma & Healthcare
Value₹150 cr (stake + primary)
[object Object][object Object][object Object][object Object][object Object][object Object][object Object][object Object]

Sources

Open in the live tracker →

Related deals